Editas醫藥 EDIT 深 滬
已收盤 09-26 16:00:00 美东时间
3.24
+0.010
+0.31%
華盛通- 最 高3.26
- 今 開3.21
- 成交量 240.07万股
- 最 低 3.01
- 昨 收 3.23
- 總市值 2.71亿
- 52周最高 3.80
- 市盈率 靜 --
- 換手率 2.87%
- 52周最低 0.9101
- 委 比 -84.84%
- 總股本 8371.29万
- 歷史最高 99.95
- 量 比 0.66
- 振 幅 7.74%
- 歷史最低 0.9101
- 每 手 1
- 風險率 2.29%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Healthcare Innovation Accelerates as Four Converging Forces Drive Early Intervention Focus
USA News Group News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, Sept. 25, 2025 /PRNewswire/ -- America's aging demographics are creating unprecedented demand for pr...
09-25 21:15
SUNSTONE HOTEL INVESTORS COMPLETES $1.35 BILLION AMENDED AND RESTATED CREDIT AGREEMENT
ALISO VIEJO, Calif., Sept. 25, 2025 /PRNewswire/ -- Sunstone Hotel Investors, Inc. (the "Company" or "Sunstone") (NYSE: SHO) announced that it has entered into a Third Amended and Restated C...
09-25 20:00
VCREDIT Holdings Announces EGM to Approve Interim Dividend
An update from VCREDIT Holdings Limited ( ($HK:2003) ) is now available. VCREDI...
09-19 12:38
OPPENHEIMER EXPANDS GLOBAL CREDIT TEAM
New European team enhances global client coverage and collaboration, with a focus on global high yield and distressed assets LONDON, Sept. 17, 2025 /PRNewswire/ -- Oppenheimer Europe Limited...
09-17 17:00
Editas Medicine Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
In the last three months, 4 analysts have published ratings on Editas Medicine ...
09-05 20:01
Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate
Editas Medicine announced the nomination of EDIT-401, an experimental gene editing therapy designed to significantly reduce LDL cholesterol (LDL-C) levels. Preclinical studies showed EDIT-401 achieved ~90% mean LDL-C reduction in non-human primates, surpassing standard therapies. The company aims to advance EDIT-401 to human proof-of-concept data by end of 2026 and has a strong cash position to support operations into the second quarter of 2027. ...
09-02 11:00
英伟达迎来一群劲敌
原标题：英伟达迎来一群劲敌 近期发布的超以太网（Ultra Ethernet，简称UE）1.0规范，为未来人工智能（AI）和高性能计算（HPC）系统定义了一套...
09-01 16:17
Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate
CAD Pharmaceuticals أعلنت شركة إديتاس ميديسين("", glands التي مقرها في كمبردج، ماساتشوستس، عن عقد ندوي patrols_ via-distance_ Online في التاسع من سبتمبر للكشف عن المرشح reimbursable_ developmounted chief. يمكن للمرتفقين الوصول إلى البث الحي والمتواجد عن طريق الرابط المذكور في محفوظات الموقع الالكتروني للشركة.}() 翻译成英文： Editas Medicine announced it will host a webinar on September 2 to reveal its lead in vivo development candidate. The live and ...
08-28 20:01
Editas Medicine to Participate in Upcoming Investor Conferences
Editas Medicine announced its participation in three upcoming healthcare conferences in September 2025, including one-on-one meetings and a fireside chat. These events will be held in Boston, MA, and New York, NY, with live webcasts available through the company’s website. Editas Medicine, a leader in gene editing focused on CRISPR/Cas12a and CRISPR/Cas9 systems, aims to develop transformative medicines for serious diseases. Access to the webcast...
08-27 13:00
VCREDIT Holdings Updates Nomination Committee Terms
VCREDIT Holdings Limited ( ($HK:2003) ) has shared an update. VCREDIT Holdings ...
08-25 23:09
